Oncotarget

Research Papers:

Combining targeted drugs to overcome and prevent resistance of solid cancers with some stem-like cell features

Elina Jokinen, Niina Laurila, Peppi Koivunen and Jussi P. Koivunen _

PDF  |  HTML  |  How to cite

Oncotarget. 2014; 5:9295-9307. https://doi.org/10.18632/oncotarget.2424

Metrics: PDF 2349 views  |   HTML 2327 views  |   ?  


Abstract

Elina Jokinen1,*, Niina Laurila1,*, Peppi Koivunen2 and Jussi P. Koivunen1

1 Department of Medical Oncology and Radiotherapy, Oulu University Hospital, University of Oulu, Oulu, Finland

2 Biocenter Oulu, Faculty of Biochemistry and Molecular Medicine and Oulu Center for Cell-Matrix Research, University of Oulu, Oulu, Finland

* These authors contributed equally to this work

Correspondence:

Jussi Koivunen, email:

Keywords: Targeted cancer therapy, resistance, cancer stem-like cells, non-small cell lung cancer

Received: May 26, 2014 Accepted: September 02, 2014 Published: September 02, 2014

Abstract

Treatment resistance significantly inhibits the efficiency of targeted cancer therapies in drug-sensitive genotypes. In the current work, we studied mechanisms for rapidly occurring, adaptive resistance in targeted therapy-sensitive lung, breast, and melanoma cancer cell lines. The results show that in ALK translocated lung cancer lines H3122 and H2228, cells with cancer stem-like cell features characterized by high expression of cancer stem cell markers and/or in vivo tumorigenesis can mediate adaptive resistance to oncogene ablative therapy. When pharmacological ablation of ALK oncogene was accompanied with PI3K inhibitor or salinomycin therapy, cancer stem-like cell features were reversed which was accompanied with decreased colony formation. Furthermore, co-targeting was able to block the formation of acquired resistance in H3122 line. The results suggest that cells with cancer stem-like cell features can mediate adaptive resistance to targeted therapies. Since these cells follow the stochastic model, concurrent therapy with an oncogene ablating agent and a stem-like cell-targeting drug is needed for maximal therapeutic efficiency.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 2424